Role of NF-κB, PI3K and AKT pathways in ASC-mediated... | Download Scientific Diagram
NF‐κB signaling in inflammation and cancer - Zhang - 2021 - MedComm - Wiley Online Library
Figure 2 from Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties | Semantic Scholar
NF‐κB signaling in inflammation and cancer - Zhang - 2021 - MedComm - Wiley Online Library
Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites | Journal of Medicinal Chemistry
Synthesis, Biological Evaluation, and Molecular Docking Study of 3-Amino and 3-Hydroxy-seco A Derivatives of α-Amyrin and 3-Epilupeol as Inhibitors of COX-2 Activity and NF-kB Activation | Journal of Natural Products
Bardoxolone methyl: drug development for diabetic kidney disease | Clinical and Experimental Nephrology
Antioxidants | Free Full-Text | Nrf2 Activation in Chronic Kidney Disease: Promises and Pitfalls
Bardoxolone methyl: drug development for diabetic kidney disease | Clinical and Experimental Nephrology
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease | Signal Transduction and Targeted Therapy
Bardoxolone methyl - IκB/IKK - NF-κB - Reference Compounds Your lab for organic synthesis
NF-kB Signaling Pathway products from Selleck Chemicals
Bardoxolone methyl breaks the vicious cycle between M1 macrophages and senescent nucleus pulposus cells through the Nrf2/STING/NF-κB pathway - ScienceDirect